Orforglipron for High Blood Pressure
Trial Summary
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. Please refer to the GZPL master protocol or consult with the study coordinators for more details.
How does the drug Orforglipron differ from other treatments for high blood pressure?
Orforglipron is unique because it is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), similar to liraglutide, which has shown potential in lowering blood pressure while also providing cardioprotective effects. This class of drugs is primarily used for diabetes but is being explored for its benefits in reducing blood pressure, offering a novel approach compared to traditional blood pressure medications.12345
What is the purpose of this trial?
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for individuals with high blood pressure who are also dealing with obesity or being overweight. Specific eligibility will be determined based on the broader GZPL master protocol, which outlines detailed inclusion and exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive orforglipron or placebo orally to evaluate efficacy and safety for hypertension in participants with obesity or overweight
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Orforglipron
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University